BioCryst Pharmaceuticals vs Tarsus Pharmaceuticals
BCRX and TARS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and TARS compare
Tarsus Pharmaceuticals is the larger company, worth 1.5 times as much as BioCryst Pharmaceuticals ($3.3B against $2.2B).
Tarsus Pharmaceuticals grew revenue faster over the last twelve months (105% versus 68.7% for BioCryst Pharmaceuticals).
Tarsus Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −7.7% compared with −40.9% at BioCryst Pharmaceuticals.
Tarsus Pharmaceuticals scores higher on the StockData Score (11 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | TARS |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $3.3B |
| Share price | $8.47 | $74.85 |
| Change, 1 year | 15.9% | 10.9% |
| Change, 5 years | −31.7% | 169% |
| Beta (5Y) | 0.80 | 0.63 |
| Employees | 435 | 370 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 4 (better) | 3 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× (better) | 5.4× |
| P/B | – | 9.5× |
| P/FCF | 5.8× (better) | 58.7× |
| FCF yield | 17.3% (better) | 1.7% |
| Fair value | – | $75.56 |
| Margin of safety | – | 0.94% |
| Growth | ||
| Revenue growth (TTM) | 68.7% | 105% (better) |
| Revenue growth, 5Y average | 118% | – |
| Profitability | ||
| Gross margin | 97.8% | – |
| Operating margin | −33.3% | −8.0% (better) |
| Net margin | −40.9% | −7.7% (better) |
| FCF margin | 39.7% (better) | 9.2% |
| Return on equity | – | −13.7% |
| Financial health | ||
| Debt / equity | – | 0.21 |
| Interest coverage | −4.2× (better) | −5.5× |
| Current ratio | 2.32 | 3.20 (better) |
| Altman Z-score | −3.68 | 7.91 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 110% |
| Held by insiders | 1.9% | 3.1% |
| Insider net buying, 12 months | −$4.1M (better) | −$20.0M |
| Short interest, % of float | 11.0% | 14.3% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- TARS stock overview
- TARS income statement
- TARS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.